TetraPhase Pharmaceuticals Secures $10,000,000 New Financing

  • Feed Type
  • Date
    9/25/2009
  • Company Name
    TetraPhase Pharmaceuticals
  • Mailing Address
    480 Arsenal Street Watertown, MA 02472
  • Company Description
    Tetraphase Pharmaceuticas is focused on the discovery and development of new tetracycline antibiotics to treat drug resistant bacterial infections. The company’s approach capitalizes on ground-breaking technology, licensed from Harvard University (Dr. Andrew Myers, Professor of Chemistry and Chemical Biology), which enables for the first time the total synthesis of tetracyclines by enabling their synthesis from simple building blocks. The technology allows extensive modification of the core molecule and synthesis of thousands of new tetracycline compounds that were previously inaccessible, dramatically expanding the universe of an existing, highly successful antibiotic class. Tetraphase has an exlusive worldwide license to the technology.
  • Website
    http://www.tphase.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $10,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.